The turnaround in business F gathered further momentum with a notable uptrend inrevenues profitability and cash flow management despite disruptions in the supply chainand mounting inflationary pressures in the macro-environment.
Dear Shareholders
The world has been gradually coming to terms with the new normal in the aftermath of agradual receding of the COVID-19 pandemic. India like the rest of the world continued toface challenges even in FY22 and the impact of the pandemic further compounded bygeo-political events continues to be felt both on the economy and communities in general.
At RPG Life Sciences the continued adoption of stringent COVID-19 protocols robustsystems and processes and digital initiatives helped mitigate the impact to a fair degree.The turnaround in business gathered further momentum with a notable uptrend in revenuesprofitability and cash flow management despite disruptions in the supply chain andmounting inflationary pressures in the macroenvironment.
During the year the Company maintained a strong focus on business continuity to ensureminimum disruptions in manufacturing activity and supply chains while looking tocontinuously improve sales and other performance metrics. Safety and wellbeing of itspeople and their families dealers customers and communities continued to remain a keyfocus area for the Company.
The Company is well poised to build on the strong operational competencies developedover the last few years. I am hopeful that the Company will continue to grow and createnew milestones in the years to come.
Harsh V. Goenka
Chairman.
